Replies to post #41591 on Biotech Values

[bio_neophyte]

CBLI - mentioned in Barron's

Cleveland BioLabs Inc. (CBLI, $6.40, $0.20, 3.2%) could benefit speculation that the government may call for a drug to treat exposure to radiation. The company expects to start human trials on its drug to protect good cells during cancer radiation this fall.